前立腺癌の化学療法と放射線治療

スポンサーリンク

概要

• 論文の詳細を見る

• The interest of many urologists in chemotherapy of carcinoma of the prostate has gradually arisen In the treatment of intractable cases to the anti-androgen therapy. The author have tried testing several anti-tumor agents using nude mice with tumors resulting from inocculation of cultured cells EB 33 which had been derived from human prostatic carcinoma tissue. The growth curve of the tumors in the tested group usually composed of 5 animals was compared to that of the control group. Three different kinds of agents were tested. Twenty mg/kg/day of 5-ftuolouracil (5-FU), 60 and 100 mg/kg/day of Futraful, a masked compound of 5-FU, and 10 mg/kg/day of cyclophosphamide (CP) were injected intraperitoneally for 14 consecutive days. Vincristine (VCR) was given at the dose of 0.45 mg/kg/day 7 times once per 3 days. CP showed the significant reduction of the tumor growth with minimal decrease of the body weight and VCR did the comparable effect with a little severer complication, but no significant changes were resulted in 5-FU or Futraful, although this compound had been reported as clinically effective. Three patients who had been refractory to the proceeding hormone therapy were treated with a combination of Futraful, CP and VCR, based upon the obtained experiluental results. The clinical result was evaluated as 0-0, 0-A5 and I-B3, respectively, according to Karnowsky's criteria. The improvement of the mode of administration will be a further subject. The radiation therapy has greatly progressed in recent years. However, it has been documented that over 7,000 rad of irradiation would be necessary for a complete remission of the prostatic cancer, because of its low sensitivity to irradiation. In order to minimize the complications caused by such a high dose radiation, the author have continued to study experimentally and clinically in different two ways, i.e. a combination of 5-FU with radiation and intra-operative irradiation. After being proven synergic in the cell culture work and the nude mouse experiment, 6,000 rad was irradiated to 3 stage C patients with administration of Futraful. All but one has been well controlled. The complications were minimal. The other 4 stage Band C patients up to date have been irradiated 3,000 rad on the average through open perineal approach. The clinical result is to be satisfied, and the trial is being carried on.

• 泌尿器科紀要刊行会の論文

著者

• 岡田 謙一郎

  大阪府立成人病センター研究所

関連論文

• 第39回日本泌尿器科学会中部総会シンポジウム2: 「前立腺癌治療の現況と問題点」
• 超音波診断の位置づけ
• ホルモン非依存性前立腺癌の治療 - 化学療法に関するまとめ -
• 膀胱頚部硬化症の内視鏡診断
• 前立腺癌の化学療法と放射線治療

スポンサーリンク